health
Diabetic drug Ozempic, now widely popular as a weight loss aid and appetite suppressant, may also act as a preventive measure against certain types of cancer, a new study has found.
Popular semaglutide injections, which belong to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, reduce the risk of liver cancer and cirrhosis in individuals suffering from both chronic liver disease and type 2 diabetes. It has been shown that , according to a study by Karolinska Institutet in Sweden.
“Our findings are interesting because there are currently no approved drugs that reduce this risk.” Lead author Axel Wester said:.
The new data, now published in the journal Gut, looked at all Swedish residents with both type 2 diabetes and chronic liver disease.
The samples were then divided into patients who took GLP-1 drugs and those who did not.
Populations that took Ozempic and the related GLP1 for long periods of time were seen to have a lower risk of these two liver diseases.
Researchers have now created a new database to study a wider range of people for even more potential results.
“Similar results would further strengthen the hypothesis that GLP1 agonists can be used to reduce the risk of severe liver disease,” said study author Hannes Hagström.
However, Wester said it would “take years” to complete a proper study on the issue.
Ozempic’s popularity has skyrocketed in recent months, especially within the Hollywood community, and reports of overdoses have increased, according to the U.S. Poison Center.
The study is also the latest in a series of claims about the drug’s positive side effects. Late last year, a study was published in the Journal of Clinical Psychiatry suggesting that taking Ozempic may help treat alcohol cravings.
Load more…
{{#isDisplay}}
{{/isDisplay}}{{#isAniviewVideo}}
{{/isAniviewVideo}}{{#isSRVideo}}
{{/isSR video}}